CBLB502 TLR5 Activation for Acute Radiation Syndrome Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical radiation countermeasures (MRCs) for acute radiation syndrome (ARS) are either ineffective, have significant side effects, or are not FDA-approved, making it challenging to find safe and effective treatments for preventing or mitigating radiation-induced tissue damage.
Innovation Solution
The use of CBLB502, a truncated derivative of the Salmonella flagellin protein, which activates Toll-like receptor 5 (TLR5) signaling, is proposed as a composition for treating or preventing ARS, administered in specific doses and regimens to ensure safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If G-CSF is used as a medical radiation countermeasure, then it may provide some protective effect against radiation, but it requires multiple injections, supportive care, and laboratory monitoring which reduces ease of operation
Solution Approach 1:
The patent extracts and utilizes endogenous protective mechanisms by activating TLR5 signaling with CBLB502, thereby eliminating the need for complex external support systems like multiple injections and laboratory monitoring required by G-CSF
Solution Approach 2:
CBLB502 triggers the body's own protective responses through TLR5 activation, making the system self-sufficient without requiring external supportive care or repeated administrations, thus resolving the contradiction between reliability and ease of operation
2Reliability
If IL-12 is used as a medical radiation countermeasure, then it may provide radiomitigation effects, but it causes substantial inflammatory toxicity which worsens harmful factors
Solution Approach 1:
The patent converts the potential harmful inflammatory response into a beneficial protective effect by using CBLB502 to activate TLR5 signaling, which induces controlled inflammatory responses that protect against radiation damage without causing the substantial inflammatory toxicity associated with IL-12
Solution Approach 2:
The patent changes the parameter of inflammatory response intensity and type by using TLR5 activation instead of direct IL-12 administration, achieving radiomitigation efficacy while avoiding excessive inflammatory toxicity through a different immunological pathway
3Reliability
If high doses of CBLB502 are administered to ensure efficacy, then radiation protection may be improved, but safety concerns increase
Solution Approach 1:
The patent optimizes the dosage parameter of CBLB502 to achieve maximum protective efficacy while minimizing adverse effects, establishing a safe and effective dose range through controlled studies that balance reliability and safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CBLB502, known as entolimod, effectively reduces morbidity and mortality from ARS by stimulating anti-inflammatory and anti-apoptotic responses, accelerating recovery, and protecting hematopoietic and gastrointestinal systems when administered within specific time frames post-radiation exposure.
Implementation Method 1
CBLB502 is a truncated derivative of the Salmonella flagellin protein that acts by triggering Toll-like receptor 5 (TLR5) signaling
Data Source
Figure 1
Figure 2
Figure 3A~3D
AI summary
This invention relates, in part, to methods and compositions that are useful for the treatment and/or prevention of various disorders, including radiation-related disorders, such as acute radiation syndrome.